Tetra Bio-Pharma (TSXV:TBP,OTCQB:TBPMF) has stepped closer to receiving fast track designation from the US Food and Drug Administration (FDA) for its drug-device combination, which aims to treat patients with incurable malignant cancer.

Monday’s (February 3) announcement follows a meeting the company held with the federal regulator to discuss the eligibility of the cannabinoid-based treatment, called CAUMZ, for the expedited review and approval path, and to provide information on the studies that will bring the product to market.


The share price for the firm rose 3.9 percent from its closing price last week and was sitting at C$0.53 as of 3:16 p.m. EST on Monday.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

The drug aims to treat cancer cachexia, a syndrome that causes weight loss, anorexia and anemia in patients with cancer. It has a high morbidity rate and doesn’t respond well to treatment, as per the FDA.

Tetra said the FDA has never approved a product that specifically targets the disorder, making it eligible for fast track designation since it addresses a currently unmet medical need.

Since the drug meets the fast track designation requirements, Tetra said it’s now able to file for the designation request, which will then be decided by the regulator within 60 days.

Drugs that receive the designation have an average review timeline of six months compared to the usual 10 months.

Along with getting the green light to apply for the fast track pathway, the FDA has also cleared Tetra to move ahead with the development of CAUMZ through the accelerated approval program.

The FDA suggested that Tetra use a patient-reported outcome instrument that demonstrates the efficacy of the drug and its benefits.

The accelerated approval program is meant for drugs that use a “surrogate endpoint” that may or may not correlate with a real clinical endpoint because the benefits are measured over a long period of time.

CAUMZ’s development will also benefit from the 505(b)(2) new drug application pathway, the company said, which prevents it from having to redo studies it has already completed and allows it to use data that wasn’t developed by Tetra.

In its review of the new drug, the FDA told Tetra that it needs to look at the interaction between the two cannabinoids, tetrahydrocannabinol and cannabidiol, used in the drug.

“Based on the FDA decisions and guidance, Tetra confirms that CAUMZ will be able to benefit from three regulatory decisions-programs: 505(b)(2) which will lower overall costs, Fast Track designation, and Accelerated Approval which may reduce the time to market,” said Tetra CEO Guy Chamberland.

Last month, the company told investors it was planning to launch its over-the-counter TERPACAN brand of hemorrhoid and back and muscle pain treatments in Canadian pharmacies by mid-2020.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

In the evolving rush of mergers and acquisitions (M&A) in the Canadian cannabis market, Canopy Growth (NASDAQ:CGC,TSX:WEED) announced it will acquire The Supreme Cannabis Company (TSX:FIRE,OTCQX:SPRWF) in a deal worth approximately C$435 million.

Meanwhile, a cannabis operator in the US confirmed this week that it will receive a financial boost from a partner to solidify its position in the burgeoning Pennsylvania state market.

Keep reading... Show less

The Board of Directors of Aphria Unanimously Recommends Shareholders Vote “For” the Arrangement

Aphria to Host Special Meeting of Shareholders on Wednesday, April 14, 2021 to Approve Proposed Aphria-Tilray Business Combination

Keep reading... Show less

Love Hemp Group PLC (AQSE: LIFE) (OTCQB: WRHLF), one of the UK’s leading CBD and Hemp product suppliers, announces that as part of the equity fundraise announced yesterday, Antony Calamita and Andrew Male, Directors of the Company, subscribed for 285,714 Ordinary Shares and 1,428,571 Ordinary Shares respectively. The subscriptions are at a price of 3.5 pence per ordinary share for a total of £60,000. Following these subscriptions, Antony Calamita is now interested in 54,385,714 Ordinary Shares, representing 8.61% of the Company’s share capital as increased by the fundraising, and Andrew Male is now interested in 6,138,196 Ordinary Shares, representing 0.97% of the Company’s issued share capital as increased by the fundraising

Further, the timetable for receipt of applications under the Broker Option, which was also announced yesterday, has been extended until 5:00 pm 9 April 2021 to capture additional interest which was unable to be completed yesterday.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, would like to provide the following dial-in information for the Company’s upcoming Annual and Special Meeting (the “Meeting”) scheduled to be held at 11:00 a.m. Eastern Daylight Time on April 12, 2021. Shareholders and proxyholders may access the Meeting via teleconference by dialing 647-723-3984 or 1-866-365-4406 from Canada or the United States, then entering participation code “8487744” followed by the pound (“#”) sign.

In consideration of the COVID-19 pandemic and the recent restrictions imposed by the Ontario Provincial Government, shareholders and proxyholders will only be able to attend the Meeting via teleconference and will not be permitted to attend the Meeting in person at the address provided on the Notice of Annual and Special Meeting of Shareholders.

Keep reading... Show less

Gage Growth Corp. (“Gage” or the “Company”) (CSE:GAGE), a leading high-quality craft cannabis brand and operator in Michigan, announced today that it has signed an agreement with Blue River™ Extracts & Terpenes (“Blue River™”) to bring the brand’s award-winning solventless technology and other trademark branded products to the state’s medical patients and cannabis consumers. The Company will have exclusive rights to Blue River™’s premium product offerings in Michigan.

Keep reading... Show less